Cocrystal Pharma, Inc. — Director's Dealing 2023

Apr 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2023-04-04

Reporting Person: FROST PHILLIP MD ET AL (Director, 10% Owner)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-04	Common Stock	P	1015229	$1.97	Acquired	1319838	Indirect

Footnotes

F1: These securities were purchased in a private transaction with the Issuer.

F2: The amount of securities beneficially owned has been adjusted for the one-for-12 reverse stock split effective October 11, 2022.

F3: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD (the "Reporting Person") is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. The Reporting Person is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.